(Reuters) – European Union’s human medicines committee (CHMP) said on Friday it is not updating its opinion on Eisai and Biogen’s Alzheimer’s drug Leqembi, after it recommended its approval in November.
The European Commission had asked the CHMP to consider information on the safety of Leqembi.
(Reporting by Christy Santhosh in Bengaluru; Editing by Tasim Zahid)
Comments